Phase I study of Carzelesin (U-80,244) given (4-weekly) by intravenous bolus schedule (Q33328419)

25 July 2017

Phase I study of Carzelesin (U-80,244) given (4-weekly) by intravenous bolus schedule (English)

1 reference

25 July 2017

Awada A

1

1 reference

25 July 2017

Punt CJ

2

1 reference

25 July 2017

Piccart MJ

3

1 reference

25 July 2017

Van Tellingen O

4

1 reference

25 July 2017

Van Manen L

5

1 reference

25 July 2017

Kerger J

6

1 reference

25 July 2017

Groot Y

7

1 reference

25 July 2017

Wanders J

8

1 reference

25 July 2017

Verweij J

9

1 reference

25 July 2017

Wagener DJ

10

1 reference

25 July 2017

language of work or name

English

0 references

publication date

1 March 1999

1 reference

British Journal of Cancer

25 July 2017

1 reference

25 July 2017

79

1 reference

25 July 2017

9-10

1 reference

25 July 2017

1454-1461

1 reference

https://scigraph.springernature.com/pub.10.1038/sj.bjc.6690232

25 July 2017

0 references

cites work

Phase I clinical and pharmacokinetic study of carzelesin (U-80244) given daily for five consecutive days.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2362731

A clinical pharmacokinetics study of carzelesin given by short-term intravenous infusion in a phase I study

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2362731

Phase I study of adozelesin (U-73,975) in patients with solid tumors

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2362731

Sequence selectivity of DNA covalent modification

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2362731

DNA damage and differential cytotoxicity produced in human carcinoma cells by CC-1065 analogues, U-73,975 and U-77,779

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2362731

Cytotoxicity and antitumor activity of carzelesin, a prodrug cyclopropylpyrroloindole analogue.

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2362731

Phase I study of adozelesin administered by 24-hour continuous intravenous infusion

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2362731

Preliminary toxicity studies with the DNA-binding antibiotic, CC-1065

31 October 2018

1 reference

12 December 2020

Reaction of the antitumor antibiotic CC-1065 with DNA: structure of a DNA adduct with DNA sequence specificity

1 reference

12 December 2020

Reaction of the antitumor antibiotic CC-1065 with DNA. Location of the site of thermally induced strand breakage and analysis of DNA sequence specificity

1 reference

12 December 2020

Fully automated high-performance liquid chromatographic method for the determination of carzelesin (U-80,244) and metabolites (U-76,073 and U-76,074) in human plasma

1 reference

12 December 2020

DNA-minor-groove alkylators, a new class of anticancer agents

1 reference

12 December 2020

Phase I study of the novel distamycin derivative tallimustine (FCE 24517)

1 reference

12 December 2020

Therapeutic efficacy of the cyclopropylpyrroloindole, carzelesin, against xenografts derived from adult and childhood solid tumors

1 reference

12 December 2020

Pharmaceutical development of a parenteral formulation of the novel anti-tumor agent carzelesin (U-80,244)

1 reference

12 December 2020

Identifiers

DOI

10.1038/SJ.BJC.6690232

1 reference

Dimensions Publication ID

25 July 2017

0 references

1 reference

25 July 2017

1 reference